keyword
MENU ▼
Read by QxMD icon Read
search

ZES

keyword
https://www.readbyqxmd.com/read/28193901/exceedingly-small-iron-oxide-nanoparticles-as-positive-mri-contrast-agents
#1
He Wei, Oliver T Bruns, Michael G Kaul, Eric C Hansen, Mariya Barch, Agata Wiśniowska, Ou Chen, Yue Chen, Nan Li, Satoshi Okada, Jose M Cordero, Markus Heine, Christian T Farrar, Daniel M Montana, Gerhard Adam, Harald Ittrich, Alan Jasanoff, Peter Nielsen, Moungi G Bawendi
Medical imaging is routine in the diagnosis and staging of a wide range of medical conditions. In particular, magnetic resonance imaging (MRI) is critical for visualizing soft tissue and organs, with over 60 million MRI procedures performed each year worldwide. About one-third of these procedures are contrast-enhanced MRI, and gadolinium-based contrast agents (GBCAs) are the mainstream MRI contrast agents used in the clinic. GBCAs have shown efficacy and are safe to use with most patients; however, some GBCAs have a small risk of adverse effects, including nephrogenic systemic fibrosis (NSF), the untreatable condition recently linked to gadolinium (Gd) exposure during MRI with contrast...
February 13, 2017: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/28185704/everolimus-versus-zotarolimus-eluting-stent-following-percutaneous-coronary-chronic-total-occlusion-intervention
#2
Pil Hyung Lee, Min Soo Cho, Seung-Whan Lee, Jung-Min Ahn, Duk-Woo Park, Soo-Jin Kang, Young-Hak Kim, Cheol Whan Lee, Seong-Wook Park, Seung-Jung Park
BACKGROUND: Although studies have demonstrated comparable efficacy and safety profiles of everolimus- and zotarolimus-eluting stents (EES and ZES, respectively) for a broad spectrum of coronary artery diseases, there is paucity of data concerning their safety and efficacy for coronary chronic total occlusions (CTOs). This study compared the clinical performance of EES and ZES following successful percutaneous coronary intervention for CTOs. METHODS: The cohort included 539 consecutive CTO patients who underwent successful PCI using EES (n=313) and ZES (n=226) between September 2006 and August 2014...
February 2, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28120558/nobori-biolimus-eluting-stents-versus-resolute-zotarolimus-eluting-stents-in-patients-undergoing-coronary-intervention-a-propensity-score-matching
#3
Ayman Tantawy, Chul Min Ahn, Dong Ho Shin, Jung Sun Kim, Byeong Keuk Kim, Young Guk Ko, Donghoon Choi, Yangsoo Jang, Meong Ki Hong
PURPOSE: To compare the 1-year outcomes of a durable polymer Zotarolimus-eluting stent (ZES) versus a biodegradable polymer Biolimus-eluting stent (BES) in patients undergoing percutaneous coronary intervention. MATERIALS AND METHODS: A total of 2083 patients from 2 different registries, 1125 treated with BES in NOBORI registry and 858 received ZES in CONSTANT registry were included in this study. Clinical outcomes were compared with the use of propensity score matching (PSM)...
March 2017: Yonsei Medical Journal
https://www.readbyqxmd.com/read/28114618/five-year-outcome-after-implantation-of-zotarolimus-and-everolimus-eluting-stents-in-randomized-trial-participants-and-nonenrolled-eligible-patients-a-secondary-analysis-of-a-randomized-clinical-trial
#4
Clemens von Birgelen, Liefke C van der Heijden, Mounir W Z Basalus, Marlies M Kok, Hanim Sen, Hans W Louwerenburg, K Gert van Houwelingen, Martin G Stoel, Frits H A F de Man, Gerard C M Linssen, Kenneth Tandjung, Carine J M Doggen, Job van der Palen, Marije M Löwik
Importance: Long-term follow-up after a clinical trial of 2 often-used, newer-generation drug-eluting stents (DESs) in a broad patient population is of interest. Comprehensive long-term outcome of eligible nonenrolled patients has never been reported. Objective: To assess 5-year safety and efficacy of 2 newer-generation DESs in randomized participants with non-ST-elevation acute coronary syndromes or stable angina and to evaluate long-term outcomes of nonenrolled eligible patients treated with the same DESs...
January 18, 2017: JAMA Cardiology
https://www.readbyqxmd.com/read/28109872/5-year-safety-and-efficacy-of-resolute%C3%A2-zotarolimus-eluting-stent-the-resolute-global-clinical-trial-program
#5
Robert W Yeh, Sigmund Silber, Lianglong Chen, Shaoliang Chen, Shirish Hiremath, Franz-Josef Neumann, Shubin Qiao, Shigeru Saito, Bo Xu, Yuejin Yang, Laura Mauri
OBJECTIVES: The authors evaluated the 5-year cumulative incidence of cardiovascular events following Resolute zotarolimus-eluting stent (R-ZES) implantation. BACKGROUND: Individual trials are often underpowered to show differences for low-frequency adverse events. The R-ZES was studied in 10 prospective clinical trials, designed with identical adverse event definitions, ascertainment, and adjudication. METHODS: The RESOLUTE Global Clinical Trial Program includes 7,618 patients treated with R-ZES: RESOLUTE first-in-human study (N = 139), RESOLUTE All Comers (N = 1,140), RESOLUTE International (N = 2,349), RESOLUTE US (N = 1,402), RESOLUTE US 38 mm (N = 114), RESOLUTE Japan (N = 100), RESOLUTE Japan Small Vessel Study (N = 65), RESOLUTE Asia (N = 311), RESOLUTE China Randomized Controlled Trial (N = 198), and RESOLUTE China Registry (N = 1,800)...
February 13, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28105994/angiographic-outcomes-of-orsiro-biodegradable-polymer-sirolimus-eluting-stents-and-resolute-integrity-durable-polymer-zotarolimus-eluting-stents-results-of-the-orient-trial
#6
Si-Hyuck Kang, Woo-Young Chung, Joo Myung Lee, Jin-Joo Park, Chang-Hwan Yoon, Jung-Won Suh, Young-Seok Cho, Joon-Hyung Doh, Jin Man Cho, Jang-Whan Bae, Tae-Jin Youn, In-Ho Chae
AIMS: We performed a randomised controlled open-label non-inferiority trial to compare angiographic outcomes between the ultra-thin strut, biodegradable hybrid polymer Orsiro sirolimus-eluting stent (O-SES) and the durable biocompatible polymer Resolute Integrity zotarolimus-eluting stent (R-ZES). METHODS AND RESULTS: A total of 372 patients planned to undergo percutaneous coronary revascularisation were randomly assigned 2:1 to treatment with O-SES or R-ZES (250 and 122 patients, respectively)...
January 20, 2017: EuroIntervention
https://www.readbyqxmd.com/read/28097810/physicochemical-and-biological-evaluation-of-a-cinnamamide-derivative-r-s-2e-1-3-hydroxypiperidin-1-yl-3-phenylprop-2-en-1-one-km-608-for-nervous-system-disorders
#7
Agnieszka Gunia-Krzyżak, Ewa Żesławska, Florence Bareyre, Wojciech Nitek, Anna M Waszkielewicz, Henryk Marona
A cinnamamide scaffold has been successfully incorporated in several compounds possessing desirable pharmacological activities in central and peripheral nervous system such as anticonvulsant, antidepressant, neuroprotective, analgesic, anti-inflammatory, muscle relaxant, and sedative/hypnotic properties. R,S-(2E)-1-(3-hydroxypiperidin-1-yl)-3-phenylprop-2-en-1-one (KM-608), a cinnamamide derivative, was synthesized, its chemical structure was confirmed by means of spectroscopy and crystallography, additionally thermal analysis showed that it exists in one crystalline form...
January 18, 2017: Chemical Biology & Drug Design
https://www.readbyqxmd.com/read/28062139/efficacy-and-safety-of-everolimus-and-zotarolimus-eluting-stents-versus-first-generation-drug-eluting-stents-in-patients-with-diabetes-a-meta-analysis-of-randomized-trials
#8
Chirag Bavishi, Usman Baber, Sadik Panwar, Stefania Pirrotta, George D Dangas, Pedro Moreno, Jacqueline Tamis-Holland, Annapoorna S Kini, Samin K Sharma
INTRODUCTION: Patients with diabetes and coronary artery disease remain at high risk for adverse cardiovascular events after percutaneous coronary intervention. The efficacy and safety of the various drug-eluting stents (DES) in patients with diabetes is unclear. METHODS: Randomized controlled trials comparing first-generation DES [paclitaxel-eluting stents (PES) and sirolimus-eluting stents (SES)] with everolimus-eluting stents (EES) and zotarolimus-eluting stents (ZES) in diabetic patients were systematically searched...
March 1, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28058079/zollinger-ellison-syndrome-a-rare-case-of-chronic-diarrhea
#9
Ali Aamar, Kamraan Madhani, Hafeezulhassan Virk, Zeeshan Butt
Zollinger-Ellison syndrome (ZES) is caused by hypersecretion of gastrin from duodenal or pancreatic gastrinomas. We report a case of a 57-year-old female who presented with chronic diarrhea. CT abdomen showed multiple liver masses. Liver biopsy suggested metastatic well-differentiated neuroendocrine tumor. Serum gastrin level was markedly elevated. MRI abdomen, somatostatin receptor scintigraphy and endoscopic ultrasound failed to reveal primary site of the tumor. Upper gastrointestinal endoscopy showed hyperplastic gastric folds and multiple duodenal ulcers consistent with ZES...
December 2016: Gastroenterology Research
https://www.readbyqxmd.com/read/28034576/comparison-of-angioscopic-findings-among-second-generation-drug-eluting-stents
#10
Yuji Nishimoto, Yasunori Ueda, Ryuta Sugihara, Ayaka Murakami, Keisuke Ueno, Yasuharu Takeda, Akio Hirata, Kazunori Kashiwase, Yoshiharu Higuchi, Yoshio Yasumura
BACKGROUND: First-generation drug-eluting stents (DES) have reduced short-term stent failure as compared to bare-metal stents due to the inhibition of neointima hyperplasia, but instead increased the risk of very-late stent failure. Although better outcomes have been reported for second-generation DES than for first-generation DES, the difference in the angioscopic findings at 1-year follow-up has not been adequately elucidated among second-generation DES. METHODS: Consecutive 161 patients who received angioscopic examination at 1 year after implantation of second-generation DES, i...
December 26, 2016: Journal of Cardiology
https://www.readbyqxmd.com/read/28028304/zollinger-ellison-syndrome-an-unusual-case-of-chronic-diarrhoea-in-a-child
#11
R Goyal, U Debi, P Dey, K K Prasad, B R Thapa
Most cases of Zollinger-Ellison syndrome (ZES) are described in adults. It is a rare disorder in childhood. Most cases present with abdominal pain due to peptic ulceration and chronic diarrhoea not responding to general measures. The symptom complex is initially confused with other more common diseases, which lead to a delay in diagnosis. We present a rare case of a-12-year boy who initially presented with abdominal pain, diarrhoea, vomiting and progressive weight loss for over a two-year period before he was finally diagnosed as a case of ZES with the primary tumour in the pancreatic head and with multiple metastasis in both the liver and lymph nodes...
December 2016: Malaysian Journal of Pathology
https://www.readbyqxmd.com/read/28017259/zotarolimus-eluting-resolute-integrity-versus-everolimus-eluting-xience-xpedition-stents-in-the-management-of-very-long-30mm-de-novo-coronary-artery-stenosis
#12
Soumya Patra, Rabindra Nath Chakraborty, Arindam Pande, Suvro Banerjee, Manabhanjan Jena, Prakash Chandra Mandal, Swapan Kumar De, Aftab Khan, Sankha Suvro Das, Debashish Ghosh, Raja Nag
BACKGROUND: Procedural and clinical outcomes in patients with very long (>30mm) coronary lesions who underwent stent-based percutaneous coronary interventions are still unfavorable. Therefore, we compared the relative efficacy and safety of resolute zotarolimus-eluting stents (R-ZES) and Xpedition everolimus-eluting stents (X-EES) for patients with de novo very long coronary lesions. METHODS: This comparative single-centre, retrospective study compared long R-ZES and X-EES in consecutive patients admitted with very long (≥30mm) native ACC/AHA type C coronary lesions in 2014...
December 15, 2016: Cardiovascular Revascularization Medicine: Including Molecular Interventions
https://www.readbyqxmd.com/read/27916746/three-year-safety-and-efficacy-of-treating-all-comers-with-newer-generation-resolute-integrity-or-promus-element-stents-in-the-randomised-dutch-peers-twente-ii-trial
#13
Liefke C van der Heijden, Marlies M Kok, Marije M Löwik, Peter W Danse, Gillian A J Jessurun, Raymond W M Hautvast, K Gert van Houwelingen, Martin G Stoel, Marc Hartmann, Gerard C Linssen, Carine J M Doggen, Clemens von Birgelen
AIM: To assess the 3-year safety and efficacy of implanting newer-generation Resolute Integrity zotarolimus-eluting stents (ZES) versus Promus Element everolimus-eluting stents (EES) in all-comers. METHODS AND RESULTS: In the randomised, multi-center, investigator-initiated DUTCH PEERS trial, a total of 1,811 all-comers were 1:1 randomly assigned to treatment with ZES versus EES. A total of 1,293 patients (72%) were treated for complex lesions and 455 patients (25%) were treated for multiple lesions...
December 6, 2016: EuroIntervention
https://www.readbyqxmd.com/read/27876250/structure-anticonvulsant-activity-studies-in-the-group-of-e-n-cinnamoyl-aminoalkanols-derivatives-monosubstituted-in-phenyl-ring-with-4-cl-4-ch3-or-2-ch3
#14
Agnieszka Gunia-Krzyżak, Dorota Żelaszczyk, Anna Rapacz, Ewa Żesławska, Anna M Waszkielewicz, Katarzyna Pańczyk, Karolina Słoczyńska, Elżbieta Pękala, Wojciech Nitek, Barbara Filipek, Henryk Marona
A series of twenty two (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH3 or 2-CH3 was designed, synthesized and evaluated for anticonvulsant activity in rodent models of seizures: maximal electroshock (MES) test, subcutaneous pentylenetetrazole (scPTZ) test, and 6-Hz test. There were identified three most active compounds: S-(2E)-N-(1-hydroxypropan-2-yl)-3-(2-methylphenyl)prop-2-enamide (5) (ED50 MES=42.56, ED50 scPTZ=58.38, ED50 6-Hz 44mA=42.27mg/kg tested in mice after intraperitoneal (i...
January 15, 2017: Bioorganic & Medicinal Chemistry
https://www.readbyqxmd.com/read/27866130/outcomes-of-stenting-extra-small-%C3%A2-2-25-mm-vessels-using-the-resolute-zotarolimus-eluting-stent-r-zes
#15
Manish A Parikh, Jonathan Soverow, Martin B Leon, Patrick Serruys, Bo Xu, Zuyi Yuan, Robayaah Zambahari, Ajay Kirtane
AIMS: We assessed long-term outcomes in patients with extra-small (XS) (≤2.25 mm) and small vessels (SV) (>2.25-2.75 mm) treated with the Resolute zotarolimus-eluting stent (R-ZES). METHODS AND RESULTS: Data from eight studies including patients with XS or SV were pooled for this analysis. Among 2,141 patients (837 XS, 1,304 SV), three-year cumulative major adverse cardiac events (15.4% vs. 11.5%; adj. HR [95% CI]: 1.3 [1.0, 1.7], p=0.12), target lesion failure (12...
November 20, 2016: EuroIntervention
https://www.readbyqxmd.com/read/27866129/long-term-outcomes-after-resolute-zotarolimus-eluting-stent-implantation-in-patients-with-st-segment-elevation-acute-myocardial-infarction-insights-from-the-resolute-all-comers-trial-and-the-resolute-global-clinical-trial-program
#16
Carlo Di Mario, Patrick W Serruys, Sigmund Silber, Shuzheng Lu, Weimin Wang, Petr Widimský, Bo Xu, Stephan Windecker
AIMS: We examined long-term outcomes after implantation of the Resolute zotarolimus-eluting stent (R-ZES) in ST-segment elevation acute myocardial infarction (STEMI) patients. METHODS AND RESULTS: We compared long-term outcomes of STEMI patients undergoing primary angioplasty <12 hours from symptom onset who were randomised to the R-ZES (n=122) or the everolimus-eluting stent (EES, n=158) in the RESOLUTE All Comers Trial after propensity score adjustment. The five-year cumulative incidence of target lesion failure (TLF) was 7...
November 20, 2016: EuroIntervention
https://www.readbyqxmd.com/read/27836296/long-term-comparative-effectiveness-of-paclitaxel-eluting-and-everolimus-eluting-stents-in-new-york
#17
Feng Qian, Ye Zhong, Edward L Hannan
OBJECTIVE: First generation paclitaxel-eluting stents (PES) and second generation everolimus-eluting stents (EES) were approved for use in percutaneous coronary interventions (PCIs) in 2004 and 2008, respectively. However, relative long-term outcomes of PES vs EES in real practice remain unclear. We sought to determine the long-term comparative effectiveness of PES vs EES using New York State (NYS) cardiac registries and to assess long-term outcomes of PES vs ZES in six "off-label" and two "high-risk" patient subgroups...
January 15, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/27822890/comparison-of-the-endothelial-coverage-in-everolimus-and-zotarolimus-eluting-stents-in-normal-atherosclerotic-and-bifurcation-rabbit-iliac-arteries
#18
Sho Torii, Gaku Nakazawa, Takeshi Ijichi, Ayako Yoshikawa, Yohei Ohno, Yuji Ikari
The aim of this study is to evaluate differences in stent endothelial coverage among the second generation of drug-eluting stents. Incomplete stent coverage is one of the major causes of late stent thrombosis. Rabbits fed a normal diet received an everolimus (Xience Prime; EES) and a zotarolimus-eluting stent (Resolute Integrity; R-ZES) in each iliac artery, followed by sacrifice at 14 and 28 days after stent implantation. In addition, a group of atherosclerotic rabbits similarly received EES and R-ZES, and were sacrificed at 28 days...
November 7, 2016: Cardiovascular Intervention and Therapeutics
https://www.readbyqxmd.com/read/27773864/comparison-of-clinical-outcomes-after-multivessel-versus-single-vessel-stenting-with-the-zotarolimus-eluting-stent-in-the-resolute-global-clinical-trial-program
#19
Ganesh Manoharan, Jorge A Belardi, Zhimin Du, Michael Lee, Shubin Qiao, Patrick W Serruys, Stephan Windecker, Bo Xu, Alan Yeung
AIMS: Our aim was to investigate whether long-term (three-year) clinical outcomes after multivessel treatment with the Resolute zotarolimus-eluting stent (R-ZES) were similar to single-vessel treatment. METHODS AND RESULTS: The RESOLUTE Global Clinical Trial Program enrolled 7,618 patients, of whom 1,562 underwent multivessel and 6,053 single-vessel treatment with the R-ZES. Patients in the multivessel group were more likely to have complex lesions (58% vs. 44%, p<0...
January 20, 2017: EuroIntervention
https://www.readbyqxmd.com/read/27761750/comparison-of-vascular-responses-after-different-types-of-second-generation-drug-eluting-stents-implantation-detected-by-optical-coherence-tomography
#20
Hirofumi Ohtani, Shigeki Kimura, Tomoyo Sugiyama, Keiichi Hishikari, Toru Misawa, Masafumi Mizusawa, Kazuto Hayasaka, Yosuke Yamakami, Keisuke Kojima, Yuichiro Sagawa, Hiroyuki Hikita, Takashi Ashikaga, Atsushi Takahashi, Mitsuaki Isobe
: Few studies have directly compared vascular responses to second-generation drug-eluting stents (DESs). We performed optical coherence tomography examinations in 56 consecutive patients with implanted single stent [19 cobalt-chromium everolimus-eluting stents (CoCr-EES), 22 platinum-chromium EES (PtCr-EES), and 15 resolute zotarolimus-eluting stents (R-ZES)] for de novo lesions, and who did not have restenosis at their 9-month follow-up. Neointimal thickness (NIT), stent apposition, and neointimal coverage were assessed in every strut...
October 19, 2016: International Journal of Cardiovascular Imaging
keyword
keyword
17621
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"